Stryker (SYK) recently received FDA clearance for its OptaBlate BVN Basivertebral Nerve Ablation System (OptaBlate BVN), a significant milestone in the treatment of chronic vertebrogenic lower back pain. The addition of the OptaBlate BVN to Stryker's pain portfolio expands its advanced pain therapy solutions for patients and represents the intersection of two of the company’s core competencies: radiofrequency ablation technology and vertebral access.As back pain remains one of the most prevalent and debilit ...

Core Insights - Stryker has received 510(k) clearance from the U.S. FDA for its OptaBlate basivertebral nerve ablation system, which targets the basivertebral nerve to provide long-lasting relief from chronic vertebrogenic low back pain [2][3] - The OptaBlate BVN system is part of Stryker's advanced pain therapy solutions and combines radiofrequency ablation technology with vertebral access [2][3] - The introduction of OptaBlate BVN aims to address the needs of patients suffering from chronic low back pain who have not found relief through traditional treatments [3][5] Product Features - The OptaBlate BVN system achieves at least a 1 cm lesion in 7 minutes, utilizing a steerable, dynamic curved introducer for targeted performance [7] - It incorporates microinfusion technology to keep the treatment zone hydrated, reducing impedance errors and preventing charring [7] - The system includes 10-gauge access tools to facilitate the procedure [7] Market Introduction - Stryker plans to showcase the OptaBlate BVN at the American Society of Pain & Neuroscience (ASPN) Annual Meeting scheduled for July 17-20 in Miami, FL [3]